Furthermore, a vast number of clinical trials have established the serum profiles of classical (leptin and adiponectin) and emergent adipokines, such as ghrelin, resistin, retinol binding protein 4 (RBP4), visfatin, chemerin, and adipocyte fatty acid-binding protein (AFABP), in NAFLD patients [8]. The gene discussed is GHRL; the disease is metabolic dysfunction-associated steatotic liver disease.